This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Native Chemical Ligation (NCL) is an important extension of the chemical ligation concept for constructing a larger polypeptide chain by the covalent condensation of two or more unprotected peptides segments. Native chemical ligation is the most effective method for synthesizing native or modified proteins of typical size (i.e., proteins< ~300 AA).
Although the disease process tends to be slowly progressive over decades, it usually remains asymptomatic until an atheroma ulcerates, leading to immediate blood clotting at the site of the atheroma ulcer. This triggers a cascade of events that leads to clot enlargement, which may quickly obstruct blood flow. A complete blockage leads to ischemia of the myocardial (heart) muscle and damage. This process is the myocardial infarction or "heart attack". If the heart attack is not fatal, fibrous organization of the clot within the lumen ensues, covering the rupture but also producing stenosis or closure of the lumen, or over time and after repeated ruptures, resulting in a persistent, usually localized stenosis or blockage of the artery lumen. Stenoses can be slowly progressive, whereas plaque ulceration is a sudden event that occurs specifically in atheromas with thinner/weaker fibrous caps that have become "unstable". Repeated plaque ruptures, ones not resulting in total lumen closure, combined with the clot patch over the rupture and healing response to stabilize the clot, are the process that produces most stenoses over time. The stenotic areas often become more stable despite increased flow velocities at these narrowings. Most major blood-flow-stopping events occur at large plaques, which, before their rupture, produced little, if any, stenosis. From clinical trials, 20% is the average stenosis at plaques that subsequently rupture, with resulting complete artery closure. Most severe clinical events do not occur at plaques that produce high-grade stenosis.
== Reproduction == Most cone snails appear to reproduce sexually, with separate sexes and internal fertilization. Varying numbers of eggs in egg capsules are laid in substrate by cone snails. Hatchlings are of two types, the veligers (larvae that swim freely) and veliconcha (baby snail).
Sources: en.wikipedia.org
Although trials are commonly conducted at major medical centers, some participants are excluded due to the distance and expenses required for travel, leading to hardship, disadvantage, and inequity for participants, especially those in rural and underserved communities. "Decentralized clinical trials" minimize or eliminates the need for patients to travel to sites, and are now more widespread; a capability improved by telehealth and wearable technologies.
== Chemistry == The method for synthesis of nicomorphine, which involves treating anhydrous morphine base with nicotinic anhydride at 130 °C, was published by Pongratz and Zirm in Monatshefte für Chemie in 1957, simultaneously with the two analogues nicocodeine and nicodicodeine in an article about amides and esters of various organic acids.
Progesterone is a progestogen, or an agonist of the nuclear progesterone receptors (PRs), the PR-A, PR-B, and PR-C. In one study, progesterone showed EC50Tooltip half-maximal effective concentration values of 7.7 nM for the human PR-A and 8.0 nM for the human PR-B. In addition to the PRs, progesterone is an agonist of the membrane progesterone receptors (mPRs), including the mPRα, mPRβ, mPRγ, mPRδ, and mPRϵ. It is also a potent antimineralocorticoid (antagonist of the mineralocorticoid receptor (MR)), as well as a very weak glucocorticoid (agonist of the glucocorticoid receptor). Progesterone does not interact significantly with the androgen receptor (AR) or with the estrogen receptor (ER). In addition to its activity as a steroid hormone, progesterone is a neurosteroid. Specifically, it is an antagonist of the sigma σ1 receptor, a negative allosteric modulator of nicotinic acetylcholine receptors, and, via its active metabolites allopregnanolone and pregnanolone, a potent positive allosteric modulator of the GABAA receptor, the major signaling receptor of the inhibitory neurotransmitter γ-aminobutyric acid (GABA).
On March 23, Twitter announced it would remove blue checkmarks from "legacy" verified accounts on April 1, or April Fools' Day. Twitter subsequently stopped distinguishing Twitter Blue subscribers from legacy verified accounts on April 2. On April 19, the Twitter Verified account tweeted that, on April 20, legacy verified checkmarks would disappear, in apparent reference to the cannabis slang number 420; Musk had previously tweeted about the April 20 date on April 11. Despite skepticism due to the date, Twitter began removing legacy checkmarks on April 20, 2023. Among those that lost their verified status included Cristiano Ronaldo and Beyoncé. Actress Halle Berry posted a meme commemorating the loss of her blue checkmark. Several figures, such as Stephen King, noted that they had not paid for verification and—in King's case—had not added a phone number to their account. While some users, such as Eliot Higgins of Bellingcat appear to have been given verification for free, others, such as actor Ryan Reynolds—whose Twitter account has 21 million followers—do not. NBC News noted that legacy verified accounts still appeared in search results filtering for just verified users. The Washington Post noted that several deceased individuals, such as basketball player Kobe Bryant, actor Chadwick Boseman, celebrity chef Anthony Bourdain, and Linkin Park vocalist Chester Bennington had a blue checkmark. Other figures with blue checkmarks include singer Michael Jackson, rapper Mac Miller, and senator John McCain.
Sources: en.wikipedia.org
== Biological Role of cGP == The hepatic production of IGF-1 is controlled by the growth hormone (GH)-IGF-1 axis. The majority of circulating IGF-1 is not bioavailable because of its affinity and binding to IGF-binding protein (IGFBP), mainly IGFBP3. IGF-1 bioactivity is therefore, tightly regulated through reversible binding with IGFBP3. It is this binding-release process that determines the amount of bioavailable IGF-1 in circulation. IGF-1 that is not bound, is cleaved into an N-terminal tripeptide, glycine-proline-glutamate (GPE) and Des-N-IGF-1. and GPE metabolizes to result in cyclic glycine proline (cGP). Unbound IGF-1, cleaved at the N-terminal, can be metabolized through a series of downstream enzymatic reactions to cGP. The N-terminal is the binding site of IGF-1 which allows cGP to retain the same binding affinity to IGFBP-3 and thus, regulates the bioavailability of IGF-1 through competitive binding with IGFBP3. An increase in cGP, would increase competitive advantage and thus, increase the amount of circulating and therefore, bioavailable IGF-1. Research shows that cGP can normalize IGF-1 function under pathophysiological conditions of increased or diminished IGF-1 bioactivity. In vitro studies show that cGP promoted the activity of IGF-1 when insufficient and inhibited the activity of IGF-1 when in excess.
Rutherford deduced the existence of the atomic nucleus through his experiments but he had nothing to say about how the electrons were arranged around it. In 1912, Niels Bohr joined Rutherford's lab and began his work on a quantum model of the atom. Max Planck in 1900 and Albert Einstein in 1905 had postulated that light energy is emitted or absorbed in discrete amounts known as quanta (singular, quantum). This led to a series of atomic models with some quantum aspects, such as that of Arthur Erich Haas in 1910 and the 1912 John William Nicholson atomic model with quantized angular momentum as h/2π. Critically, Nicholson successfully reproduces atomic spectral lines, a challenge that Bohr's model would also need to overcome. When Bohr learned from a friend about Balmer's compact formula for the spectral line data, Bohr quickly realized his model would match it in detail. In 1913, Bohr published a trilogy of papers developing his model of the atom based on two hypothesis: 1) an electron could change states only by "quantum leaps" and 2) the jump corresponds to a emission of light according to Planck relation. With these assumptions, the instability of the older models becomes irrelevant and the classical electrodynamics of Maxwell is considered invalid. Using circular orbits for simplicity, Bohr could then derived Balmer's spectral formula. Balmer's formula contained a constant now known as the Rydberg constant with a value known only by matching experimental results.
=== Food preservative === In foods, TBHQ is used as an antioxidant preservative for unsaturated vegetable oils and many edible animal fats. It does not cause discoloration even in the presence of iron, and does not change flavor or odor of the material to which it is added. It can be combined with other preservatives such as butylated hydroxyanisole (BHA). As a food additive, its E number is E319. It is added to a wide range of foods. Its primary advantage is extending storage life.
The 16-bit A register is the primary arithmetic and logic accumulator. The 16-bit B register is used for double-length arithmetic operations. The 16-bit program counter holds the address of the next instruction. A carry flag indicates arithmetic overflow. A 16-bit X index register provides for modification of the address of operands. The instruction set has 72 arithmetic, logic, I/O and flow-control instructions. Input/output instructions use the A register and separate input and output 16-bit buses. A 10-bit I/O control bus, consisting of 6 bits of device address information and 4 bits of function selection, is used. The basic processor has a single interrupt signal line, and an option provided up to 48 interrupts. In addition to a front-panel display of lights and toggle switches, the system supports different types of input/output devices. A Teletype Model 33 ASR teleprinter can be used as a console I/O device and (in the most basic systems) to load and store data to paper tape. Smaller systems typically use a high-speed paper-tape reader and punch for data storage. The Honeywell family of peripherals included card readers and punches, line printers, magnetic tape, and both fixed-head and removable hard disk drives. A rack-mounted configuration weighs around 120 pounds (54 kg) and used 475 watts of power. Honeywell advertised the system as the first minicomputer selling for less than $10,000. The Honeywell 316 has the distinction of being the first computer displayed at a computer show with semiconductor RAM memory.
=== In film === The sedative effects of Trimipramine in off-prescription, recreational use are described in the 1987 film Withnail and I where the eponymous character declares "This is the plan. We get in there and get wrecked, then we'll eat a pork pie, then we'll drop a couple of Surmontil-50's each. That means we'll miss out Monday but come up smiling Tuesday morning."
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.